Presence of Ga1-α1,3Gal epitope on xenogeneic lines: Implications for cellular gene therapy based on the encapsulation technology

Xenotransplantation

Volumn 10, Issue 3, 2003, Pages 204-213

  Déglon, Nicole ^a,b   Aubert, Vincent ^a   Spertini, François ^a   Winkel, Laurence ^a,b   Aebischer, Patrick ^a,b  

^a University of Lausanne Medical Center   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

1,2 fucosyltransferase; Central nervous system; Encapsulation; Ga1 1,3 Ga1 epitope; Gene therapy; Xenotransplantation

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; FUCOSYLTRANSFERASE; GALACTOSYLGALACTOSE; GALACTOSYLTRANSFERASE; UNCLASSIFIED DRUG; COMPLEMENTARY DNA; DISACCHARIDE; EPITOPE; GALACTOSIDE 2 ALPHA L FUCOSYLTRANSFERASE; GALACTOSIDE 2-ALPHA-L-FUCOSYLTRANSFERASE; GALACTOSYL (1 3)GALACTOSE; GALACTOSYL-(1-3)GALACTOSE; PRIMER DNA; RECOMBINANT PROTEIN;

ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD BRAIN BARRIER; CELL ENCAPSULATION; CELL KILLING; CELL LINE; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CORRELATION ANALYSIS; CYTOLYSIS; CYTOTOXICITY; DEGENERATIVE DISEASE; FLUORESCENCE ACTIVATED CELL SORTING; GENE THERAPY; HAMSTER; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT; XENOTRANSPLANTATION; ANIMAL; C3H MOUSE; CHO CELL; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; NUCLEOTIDE SEQUENCE; SPLEEN;

ANIMALS; BASE SEQUENCE; CELL LINE; CHO CELLS; CRICETINAE; CYTOTOXICITY, IMMUNOLOGIC; DISACCHARIDES; DNA PRIMERS; DNA, COMPLEMENTARY; EPITOPES; FLOW CYTOMETRY; FUCOSYLTRANSFERASES; HUMANS; LYMPHOCYTES; MICE; MICE, INBRED C3H; RECOMBINANT PROTEINS; SPLEEN; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0042346188     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3089.2003.00110.x     Document Type: Article

References (49)

1. PLATT JL, FISCHEL RJ, MATAS AJ et al. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214.
2. KAPLON RJ, MICHLER RE, Xu H et al. Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. Transplantation 1995; 59: 1.
3. GALILI U, SWANSON K. Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after divergence of apes from monkeys. Proc Natl Acad Sci USA 1991; 88: 7401.
4. JOZIASSE DH, SHAPER JH, VAN DEN EIJNDEN, DH, VAN TUNEN AJ, SHAPER NL. Bovine α1-galactosyltransferase: isolation and characterization of a cDNA clone. J Biol Chem 1989; 264: 14290.
5. LARSEN RD, RIVERA-MARRERO C, ERNST LK, CUMMINGS RD. Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Ga1:β-DGa1(1,4)-D-GlcNac α(1,3)-galactosyltransferase cDNA. J Biol Chem 1990; 265: 7055.
6. GALILI U. Interaction of the natural anti-Ga1 antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993; 14: 480.
7. MCMORROW IM, COMRACK CA, SACHS DH, DERSIMONIAN H. Heterogeneity of human anti-pig natural antibodies cross reactive with the Ga1 (α1,3) Galactose epitope. Transplantation 1997; 64: 501.
8. PARKER W, SAADI S, LIN SS et al. Transplantation of discordant xenografts: a challenge revisited. Immunol Today 1996; 17: 373.
9. SANDRIN MS, FODOR WL, MOUHTOURIS E et al. Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1995; 1: 1261.
10. SHARMA A, OKABE J, BIRCH P et al. Reduction in the level of Ga1 (α1,3) Ga1 in transgenic mice and pigs by the expression of an α(1,2)fucosyltransferase. Proc Natl Acad Sci USA 1996; 93: 7190.
11. AEBISCHER P, WINN SR, TRESCO PA, JAEGER CB, GREENE LA. Transplantation of polymer encapsulated neurotransmitter secreting cells: effect of the encapsulation technique. J Biomech Eng 1991; 113: 178.
12. AEBISCHER P, POCHON NA-M, HEYD B et al. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymerencapsulated xenogenic cell line engineered to secrete hCNTF. Hum Gene Ther 1996; 7: 851.
13. RÉGULIER E, SCHNEIDER B, DÉGLON N, BEUZARD Y, AEBISCHER P. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther 1998; 5: 1014.
14. 2 myoblasts. Hum Gene Ther 1996; 7: 2135.
15. AEBFSCHER P, SCHLUEP M, DÉGLON N et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med 1996; 2: 696.
16. HAYES CE, GOLDSTEIN IJ. An α-D-galactosyl-binding lectin from Bandeiraea simplicifolia seeds. J Biol Chem 1974; 249: 1904.
17. MATSUMOTO I, OSAWA T. Purification and characterization of an anti-H(O) phytohemagglutinin of Ulex europeus. Biochim Biophys Acta 1969; 194: 180.
18. KRUISBEEK AM. Isolation and fractionation of mononuclear cell populations. In: COLIGAN JE, KRUISBEEK AM, MARGULIES DH, SHEVACH EM, STROBER W, eds. Current Protocols of Immunology. Vol. 1. John Wiley & Sons, Inc, 1996: Chapter. 3.1.1.
19. LARSEN RD, ERNST LK, NAIR RP, LOWE JB. Molecular cloning, sequence, and expression of a human GDP-L-fucose: β-D-galactoside 2-α-L-fucosyltransferase cDNA that can form the H blood group antigen. Proc Natl Acad Sci USA 1990; 87: 6674.
20. LAVECCHIO JA, DUNNE AD, EDGE ASB. Enzymatic removal of alpha-galactosyl epitopes from porcine endothelial cells diminishes the cytotoxic effect of natural antibodies. Transplantation 1995; 60: 841.
21. COOPER DKC, KOREN E, ORIOL R. Oligosaccharides and discordant xenotransplantation. Immunol Rev 1994; 141: 31.
22. PLATT JL, HOLZKNECHT ZE. Porcine platelet antigens recognized by human xenoreactive natural antibodies. Transplantation 1994; 57: 327.
23. COTTERELL AH, COLLINS BH, PARKER W, HARLAND RC, PLATF JL. The humoral immune response in humans following cross-perfusion of porcine organs. Transplantation 1995; 60: 861.
24. GELLER RL, RUBINSTEIN P, PLATT JL. Variation in expression of porcine xenogeneic antigens. Transplantation 1994; 58: 272.
25. LEVANTHAL JR, JOHN R, FRYER JP et al. Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Results of in vitro and in vivo studies. Transplantation 1995; 59: 294.
26. COOPER DK, GOOD AH, YE Y et al. Specific intravenous carbohydrate therapy: a new approach to the inhibition of antibody-mediated rejection following ABO-incompatible allografting and discordant xenografting. Transplant Proc 1993; 25: 377.
27. TAKEUCHI Y, COSSET F-L, LACHMANN PJ et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994; 68: 8001.
28. COSSET F-L, TAKEUCHI Y, BATTINI J-L, WEISS RA, COLLINS MKL. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430.
29. RUSSELL DW, BERGER MS, MILLER AD. The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum Gene Ther 1995; 6: 635.
30. PENSIERO MN, WYSOCKI CA, NADER K, KIKUCHI GE. Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum Gene Ther 1996; 7: 1095.
31. ROLLINS SA, BIRKS CW, SQUINTO SP, ROTHER RP. Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: strategies for evading the humoral immune response. Hum Gene Ther 1996; 7: 619.
32. AGRAWAL RS, KARHU K, LAUKKANEN J et al. Complement and anti-α-galactosyl natural antibody-mediated inactivation of murine retrovirus occurs in adult serum but not umbilical cord serum. Gene Ther 1999; 6: 146.
33. AEBISCHER P, BUCHSER E, JOSEPH JM et al. Transplantation in humans of encapsulated xenogenic cells without immunosuppression. Transplantation 1994; 58: 1275.
34. BUCHSER E, GODDARD M, HEYD B et al. Immunoisolated xenogeneic chromaffin cell therapy for chronic pain: initial clinical experience. Anesthesiology 1996; 85: 1005.
35. SANDRIN MS, MCKENZIE IFC. Galα(1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies. Immunol Rev 1994; 141: 169.
36. MASON JM, GUZOWSKI DE, GOODWlN LO et al. Human serum-resistant retroviral vector particles from galactosyl(α1)galactosyl-containing nonprimate cell lines. Gene Ther 1999; 6: 1397.
37. MCMORROW IM, COMRACK CA, SACHS DH, DERSIMONIAN H. Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(α1,3)Galactose epitope. Transplantation 1997; 64: 501.
38. BUONOMANO R, TINGUELY C, RIEBEN R, MOHACSI PJ, NYDEGGER UE. Quantification and characterization of anti-Gal-α1-Gal antibodies in sera of 200 healthy persons. Xenotransplantation 1999; 5: 173.
39. PARKER W, BRUNO D, PLATT JL. Xenoreactive natural antibodies in the world of natural antibodies: typical or unique? Trans Immunol 1995; 3: 181.
40. MORGAN BP, CAMPBELL AK, COMPSTON DAS. Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis. Lancet 1984; 2: 251.
41. DUJARDIN BCG, DRIEDJK PC, ROIJERS AFM, OUT TA. The determination of the complement components Clq, C4 and C3 in serum and cerebrospinal fluid by radioimmunoassay. J Immunol Metho 1985; 80: 227.
42. GALILI U, TIBELL A, SAMUELSSON B, RYDBERG L, GROTH C. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. Transplantation 1995; 59: 1549.
43. RYDBERG L, CAIRNS TDH, GROTH C-G et al. Specificities of human IgM and IgG anticarbohydrate xenoantibodies found in the sera of diabetic patients grafted with fetal pig islets. Xenotransplantation 1994; 1: 69.
44. RYDBERG L, BJÖRCK S, HALLBERG E et al. Extracorporal ('ex vivo') connection of pig kidneys to humans. II. The antipig antibody response. Xenotransplantation 1996; 3: 340.
45. LARSSON LC, CZECH KA, WIDNER H, KORSGREN O. Discordant neural tissue xenografts survive longer in immunoglobulin-deficient mice. Transplantation 1999; 68: 1153.
46. BARKER RA, DUNNETT SB, RICHARDS A. The rejection of neural xenotransplants: a role for antibodies. Transplantation 1999; 68: 1091.
47. GROTH CG, KORSGREN O, TIBELL A et al. Transplantation of porcine fetal pancreas to diabetic patients. Lancet 1994; 344: 1402.
48. ST HILLAIRE M, SHANNON K, SCHUMACHER J et al. Transplantation of fetal porcine striatal cells in Huntington's disease: preliminary safety and efficacy results. Neurology 1998; 50: A80.
49. ELLIAS SA, PALMER P, KOTT HS et al. Transplantation of fetal porcine ventral mesencephalic cells for treatment of Parkinson's disease: one year safety and efficacy results. Neurology 1998; 50: A80.